儿童风湿病患者接种COVID-19 mRNA疫苗的体液与细胞免疫原性、有效性及安全性:一项前瞻性队列研究
在荷兰乌得勒支Wilhelmina儿童医院风湿科开展前瞻性队列研究,纳入157例儿童自身免疫炎症性风湿病患者(88%为幼年特发性关节炎),其中137例完成全程接种、20例未接种。接种后抗体几何平均浓度在阳性阈值以上,但使用生物制剂者抗体水平显著较低(调整后GMC比值0.38,95%CI 0.21-0.70);T细胞反应除2例(9%)外均充足。全程接种者报告COVID-19的调整后发生率显著低于未接种者(HR 0.53,95%CI 0.29-0.97),接种后JIA疾病活动度评分无显著差异,未报告严重不良事件。
要点
- 全程接种者报告COVID-19的调整后发生率显著低于未接种者(HR 0.53,95%CI 0.29-0.97)。
- 使用生物制剂者接种后抗体水平显著低于未使用者(调整后GMC比值0.38,95%CI 0.21-0.70)。
- 接种后JIA疾病活动度评分无显著差异,未报告严重不良事件。
核心结论
- COVID-19 mRNA疫苗在大量使用免疫抑制药物的儿童自身免疫炎症性风湿病患者中具有免疫原性(体液和细胞免疫)、有效性和安全性。
研究设计与样本
- 在荷兰乌得勒支Wilhelmina儿童医院风湿科开展的前瞻性队列研究,纳入157例儿童自身免疫炎症性风湿病患者,其中88%为幼年特发性关节炎。
- 2021年3月至2022年8月期间在常规门诊就诊时登记疫苗接种日期、COVID-19病例和疫苗相关不良事件。
- 接种后从血清样本中检测SARS-CoV-2 IgG抗体水平和T细胞反应,并从电子病历中收集临床和药物治疗数据。
- 采用时变Cox回归分析比较接种与未接种患者COVID-19发生率。
主要发现
- 137例患者完成全程接种,其中47%在接种时使用生物制剂;20例未接种。
- 接种后SARS-CoV-2抗体几何平均浓度在使用和不使用生物制剂的患者中均高于阳性阈值,但使用生物制剂者抗体水平显著较低(调整后GMC比值0.38,95%CI 0.21-0.70)。
- T细胞反应除2例(9%)外均充足。
- 全程接种患者报告COVID-19的调整后发生率显著低于未接种患者(HR 0.53,95%CI 0.29-0.97)。
- 接种后JIA疾病活动度评分无显著差异,未报告严重不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate immunogenicity, effectiveness and safety of COVID-19 vaccination in patients with pediatric autoimmune inflammatory rheumatic disease (pedAIIRD). METHODS: A prospective cohort study was performed at the pediatric rheumatology department of the Wilhelmina Children's Hospital in Utrecht, the Netherlands. Vaccination dates, COVID-19 cases and vaccine-related adverse events (AEs) were registered for all pedAIIRD patients during regular clinic visits from March 2021 - August 2022. SARS-CoV-2 IgG antibody levels and T-cell responses were measured from serum samples after vaccination, and clinical and drug therapy data were collected from electronic medical records. Rate of COVID-19 disease was compared between vaccinated and unvaccinated patients in a time-varying Cox regression analysis. RESULTS: A total of 157 patients were included in this study and 88 % had juvenile idiopathic arthritis (JIA). One hundred thirty-seven patients were fully vaccinated, of which 47 % used biological agents at the time of vaccination, and 20 patients were unvaccinated. Geometric mean concentrations (GMCs) of post-vaccine antibody levels against SARS-CoV-2 were above the threshold for positivity in patients who did and did not use biological agents at the time of vaccination, although biological users demonstrated significantly lower antibody levels (adjusted GMC ratio: 0.38, 95 % CI: 0.21 - 0.70). T-cell responses were adequate in all but two patients (9 %). The adjusted rate of reported COVID-19 was significantly lower for fully vaccinated patients compared to non-vaccinated patients (HR: 0.53, 95 % CI: 0.29 - 0.97). JIA disease activity scores were not significantly different after vaccination, and no serious AEs were reported. CONCLUSIONS: COVID-19 mRNA vaccines were immunogenic (both cellular and humoral), effective and safe in a large cohort of pedAIIRD patients despite their use of immunosuppressive medication.
引用
- Hamad Saied M, van Straalen JW, de Roock S, et al. Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study. Vaccine. 2024. PMID: 38262809. doi:10.1016/j.vaccine.2024.01.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。